Everything below concerns thymosin alpha 1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
== Contraindications == Prucalopride is contraindicated where there is hypersensitivity to the active substance or to any of the excipients, renal impairment requiring dialysis, intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract, such as Crohn's disease, and ulcerative colitis and toxic megacolon/megarectum.
The disproportionate results of the trade notwithstanding, Bagwell eventually became acquainted with Andersen and they formed a friendship. "I knew LA and I love him," Bagwell asserted. "He used to make fun of me when I was playing bad. He said, 'you're making me look bad, you have to step it up.' Look up his numbers. He was pretty good at what he did."
== External links == JRT - Isomer Design LSD-Inspired Drug Reverses Psychosis Brain Damage Without Hallucinations - Neuroscience News Scientists Flip Two Atoms in LSD – And Unlock a Game-Changing Mental Health Treatment - SciTechDaily A New Form of LSD to Treat Schizophrenia - Psychology Today
=== Football clubs === In the 1960s, Inter Milan has its greatest period of success known as [La] Grande Inter ("Great Inter"), achieved when Helenio Herrera was their manager. He won seven trophies with the club. In 2004, Ferruccio Mazzola, Inter player during that period, accused him of distributing performance-enhancing drugs, including amphetamines, among the team players, especially the substitute players "who often served as guinea pigs for trying new pills and see if they worked." When he found out that some in the team were spitting them out, he dissolved them in coffee to make sure they were consumed, a practice known as Caffè di Herrera ("Herrera's Coffee"). In 2010, Inter sued Mazzola but lost the case, the court believed him. One of the reasons he spoke up were the serious medical conditions and/or deaths of some of his former members: Giuliano Taccola, then team's captain Armando Picchi (died aged 36 due to cancer), Marcello Giusti, Carlo Tagnin, Mauro Bicicli, Ferdinando Miniussi, Enea Masiero and Pino Longoni. He suspected the drugs to be the cause of their sufferings. in 2015, his brother Sandro, who denied everything at the beginning, admitted that the incidents happened. In the 1970s performance-enhancing drugs were used on a regular basis according to witnesses of that period, mostly in Ajax, Feyenoord and AZ Alkmaar during competitive matches, including the 1970 and 1972 Intercontinental Cups won by the first two cited clubs. Jan Peters recounted drug use before the big games. They seemed to work as he felt energy boosts and euphoria.
Sources: en.wikipedia.org
In 2001, the entire line was facelifted with new styling, a revised suspension, and a new audio system. For North America, ES models received rear disc brakes and a stiffer suspension. The 1.8 L engine was increased to 2.0 L for the ES models, and was optional on the LX model, becoming the 2.0LX. The standard 2001 Protegé LX engine was the carryover 1.6 L ZM-DE. A 2.0-litre, petrol engine appeared in 2001 on the Japanese market Sport 20. In 1999, Ford of Japan ceased to market Mazda-based models, and the Ford Laser, along with the Ixion, Telstar, and Festiva, was discontinued.
=== Cor–Cz === Robert Corey (1897–1971). American protein chemist at Caltech, known for work with Linus Pauling on the α-helix and β-sheet. Member Natl. Acad. Sci. USA. Carl Ferdinand Cori (1896–1984). American biochemist at Washington University and Albert Einstein College of Medicine, who worked on glycogen. Nobel Prize in Physiology or Medicine (1947). Member Natl. Acad. Sci. USA. Gerty Cori (1896–1957). Czech-American biochemist at Washington University, known for glycogen research. Nobel Prize in Physiology or Medicine (1947). Athel Cornish-Bowden (b. 1943). British enzymologist at the CNRS, Marseille. He has contributed to the development of metabolic control analysis, and is the author of Fundamentals of Enzyme Kinetics. Suzanne Cory (b. 1942). Australian molecular biologist known fotr work on the genetics of the immune system, at the Walter and Eliza Hall Institute of Medical Research, Melbourne. Peter Coveney (b. 1958). British Computational molecular biology specialist at University College London, University of Amsterdam and Yale. Nicholas R. Cozzarelli (1938–2006). American biochemist at UC Berkeley, and former editor-in-chief of the Proceedings of the National Academy of Sciences. Member Natl. Acad. Sci. USA. Gerald Crabtree (b. 1946). American biochemist at Stanford, known for defining the Ca2+-calcineurin-NFAT signalling pathway, pioneering the development of synthetic ligands for regulation of biological processes. Robert K. Crane (1919–2010).
There are two diametrically opposed definitions of the dog year, primarily used to approximate the equivalent age of dogs and other animals with similar life spans. Both are based upon a popular myth regarding the aging of dogs that states that a dog ages seven years in the time it takes a human to age one year.
=== SNP microarrays === In high-density oligonucleotide SNP arrays, hundreds of thousands of probes are arrayed on a small chip, allowing for many SNPs to be interrogated simultaneously. Because SNP alleles only differ in one nucleotide and because it is difficult to achieve optimal hybridization conditions for all probes on the array, the target DNA has the potential to hybridize to mismatched probes. This is addressed somewhat by using several redundant probes to interrogate each SNP. Probes are designed to have the SNP site in several different locations as well as containing mismatches to the SNP allele. By comparing the differential amount of hybridization of the target DNA to each of these redundant probes, it is possible to determine specific homozygous and heterozygous alleles. Although oligonucleotide microarrays have a comparatively lower specificity and sensitivity, the scale of SNPs that can be interrogated is a major benefit. The Affymetrix Human SNP 5.0 GeneChip performs a genome-wide assay that can genotype over 500,000 human SNPs.
Moore supports a balance between securing the United States' borders and creating pathways to citizenship for those already in the country. In June 2023, Moore said that he supported efforts to strengthen the federal temporary protected status policy for immigrants living in the United States. In June 2024, after a man who had entered the United States illegally was arrested in connection with the murder of Rachel Morin, Moore blamed congressional inaction on the issue of immigration as well as conditions at the Mexico–United States border for Morin's killing. In June 2023, after multiple Republican governors sent members of their state national guards to the southern border, Moore told WRC-TV that he did not support sending members of the Maryland National Guard to the border. In January 2025, he declined to say if he would deploy Maryland National Guard members at the southern border if asked by the federal government. Moore also advised local jurisdictions to "follow the Constitution" when cooperating with federal immigration efforts. In May 2025, he signed into law the Maryland Values Act, which prohibits federal law enforcement from conducting immigration actions at sensitive locations. In April 2025, Moore condemned the Trump administration's deportation of Kilmar Abrego Garcia on the grounds of inadequate due process, saying that "no one should be deported to the very county where a judge determined they will face persecution" and calling on the federal government to "correct" their error.
Sources: en.wikipedia.org
Injury in animals is damage to the body caused by wounding, change in pressure, heat or cold, chemical substances, venoms and biotoxins. Injury prompts an inflammatory response in many taxa of animals; this prompts wound healing, which may be rapid, as in the Cnidaria.
== Medical uses == Oveporexton is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults. Narcolepsy type 1 is a rare, lifelong neuropsychiatric sleep disorder. It is caused by the loss of brain cells that produce orexin, a chemical messenger that regulates wakefulness, sleep, and muscle tone. Without orexin, the brain struggles to maintain alertness or to control the boundary between sleep and waking. The result is a cluster of disabling symptoms, including excessive daytime sleepiness, cataplexy (sudden muscle weakness triggered by strong emotions such as laughter), sleep paralysis, hallucinations at the edge of sleep or waking, and disrupted nighttime sleep. The effectiveness and safety of oveporexton were evaluated in two randomized, double-blind, placebo-controlled 12-week studies enrolling 273 adults with narcolepsy type 1. Across both studies, participants taking oveporexton 2 mg showed improvements in their ability to stay awake during the day compared with those receiving placebo. Participants also reported substantially less daytime sleepiness, a significant reduction in cataplexy episodes, and meaningful improvement across the full spectrum of narcolepsy symptoms, including sleep paralysis, hallucinations, and disrupted nighttime sleep.
Dyck, Peter J.; Overland, Carol J.; Low, Phillip A.; Litchy, William J.; Davies, Jenny L.; Dyck, P. James B.; O'Brien, Peter C. (August 2010). "Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial: Cl vs. NPhys Trial". Muscle & Nerve. 42 (2): 157–164. doi:10.1002/mus.21661. PMC 2956592. PMID 20658599. Vitale, G.I.; Quatrale, R.P.; Giles, P.J.; Birnbaum, J.E. (July 1986). "Electrical field stimulation of isolated primate sweat glands". British Journal of Dermatology. 115 (1): 39–47. doi:10.1111/j.1365-2133.1986.tb06218.x. PMID 3524654. S2CID 23529777. Freedman, Barry I.; Bowden, Donald W.; Smith, Susan Carrie; Xu, Jianzhao; Divers, Jasmin (January 2014). "Relationships between electrochemical skin conductance and kidney disease in Type 2 diabetes". Journal of Diabetes and Its Complications. 28 (1): 56–60. doi:10.1016/j.jdiacomp.2013.09.006. PMC 3877197. PMID 24140119. Ramachandran, Ambady; Moses, Anand; Shetty, Samith; Thirupurasundari, Chandragiri Janakiraman; Seeli, Abraham Catherin; Snehalatha, Chamukuttan; Singvi, Sunil; Deslypere, Jean-Paul (June 2010). "A new non-invasive technology to screen for dysglycaemia including diabetes". Diabetes Research and Clinical Practice. 88 (3): 302–306. doi:10.1016/j.diabres.2010.01.023. PMID 20188429. Raisanen, Anu; Eklund, Jyrki; Calvet, Jean-Henri; Tuomilehto, Jaakko (June 2014). "Sudomotor Function as a Tool for Cardiorespiratory Fitness Level Evaluation: Comparison with Maximal Exercise Capacity". International Journal of Environmental Research and Public Health.
== Etymology and regional names == The name "bilberry" appears to have a Scandinavian origin, possibly from as early as 1577, while the earliest known English use of the name "blueberry" dates back to 1594, appearing in the Acts of Parliament of Scotland. The name "bilberry" is similar to the Danish word bølle for whortleberry with the addition of "berry". In Scandinavian languages, terms for bilberries have names with the meaning "blueberry", such as blåbär in Swedish and blåbær in Danish and Norwegian. The bilberry (especially Vaccinium myrtillus) may be called blaeberry in Scottish and Northern English regional dialects, whortleberry in southern England, and fraochán in Ireland.
Acoustic metamaterials, sometimes referred to as sonic or phononic crystals, are architected materials designed to manipulate sound waves or phonons in gases, liquids, and solids. By tailoring effective parameters such as bulk modulus (β), density (ρ), and in some cases chirality, they can be engineered to transmit, trap, or attenuate waves at selected frequencies, functioning as acoustic resonators when local resonances dominate. Within the broader field of mechanical metamaterials, acoustic metamaterials represent the dynamic branch where wave control is the primary goal. Acoustic metamaterials control, direct and manipulate sound in the form of sonic, infrasonic or ultrasonic waves in gases, liquids and solids. As with electromagnetic waves, sonic waves can exhibit negative refraction. Control of sound waves is mostly accomplished through the bulk modulus β, mass density ρ and chirality. The bulk modulus and density are analogs of permittivity and permeability in electromagnetic metamaterials. Related to this is the mechanics of sound wave propagation in a lattice structure. Also materials have mass and intrinsic degrees of stiffness. Together, these form a resonant system and the mechanical (sonic) resonance may be excited by appropriate sonic frequencies (for example audible pulses). Willis materials exhibit additional nonlocal material parameters for elastic-wave manipulation—analogous to the bianisotropic moduli in electromagnetic media—that couple stress with particle velocity and linear momentum with strain, known as Willis couplings. They are named after J. R.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.